Q: What is Protalix BioTherapeutics, Inc. Common Stock's WACC?

Protalix BioTherapeutics, Inc. Common Stock (PLX) has a Weighted Average Cost of Capital (WACC) of 7.59%. This is calculated using a Cost of Equity of 7.59% (via CAPM with a beta of 0.68) and a pre-tax Cost of Debt of 5.00%, with an equity weight of 100.00% in the capital structure.

Q: Is Protalix BioTherapeutics, Inc. Common Stock's WACC high or low?

Protalix BioTherapeutics, Inc. Common Stock's WACC of 7.59% is below the typical range of 8-12% for most companies, indicating relatively low cost of capital and lower risk. WACC is used as the discount rate in DCF valuations — a lower WACC results in higher present values of future cash flows.

Q: How is Protalix BioTherapeutics, Inc. Common Stock's WACC calculated?

Protalix BioTherapeutics, Inc. Common Stock's WACC is calculated using the formula: WACC = (E/V × Re) + (D/V × Rd × (1-T)). The Cost of Equity (Re) of 7.59% is derived from the CAPM model using a beta of 0.68. The pre-tax Cost of Debt (Rd) is 5.00%. The capital structure is 100.00% equity and 0.00% debt.

Question 1

What is Protalix BioTherapeutics, Inc. Common Stock's WACC?

Accepted Answer

Protalix BioTherapeutics, Inc. Common Stock（PLX） WACC 解读

Protalix BioTherapeutics, Inc. Common Stock（PLX）当前估算的 WACC 为 7.59%。其中股权成本为 7.59%，税前债务成本为 5.00%，股权权重为 100.00%。这个折现率可以直接作为 DCF 估值和资本结构判断的起点。

处于相对较低区间，通常意味着资本成本较低、估值折现压力更小。

Question 2

Is Protalix BioTherapeutics, Inc. Common Stock's WACC high or low?

Accepted Answer

Protalix BioTherapeutics, Inc. Common Stock（PLX） WACC 解读

Protalix BioTherapeutics, Inc. Common Stock（PLX）当前估算的 WACC 为 7.59%。其中股权成本为 7.59%，税前债务成本为 5.00%，股权权重为 100.00%。这个折现率可以直接作为 DCF 估值和资本结构判断的起点。

处于相对较低区间，通常意味着资本成本较低、估值折现压力更小。

Question 3

How is Protalix BioTherapeutics, Inc. Common Stock's WACC calculated?

Accepted Answer

Protalix BioTherapeutics, Inc. Common Stock（PLX） WACC 解读

Protalix BioTherapeutics, Inc. Common Stock（PLX）当前估算的 WACC 为 7.59%。其中股权成本为 7.59%，税前债务成本为 5.00%，股权权重为 100.00%。这个折现率可以直接作为 DCF 估值和资本结构判断的起点。

处于相对较低区间，通常意味着资本成本较低、估值折现压力更小。

Protalix BioTherapeutics, Inc. Common Stock (PLX) — WACC 分析

WACC 构成

解读

Protalix BioTherapeutics, Inc. Common Stock（PLX）WACC：7.59%

WACC计算器

Protalix BioTherapeutics, Inc. Common Stock（PLX） WACC 解读

PLX 公司分析

PLX DCF 估值

继续做同行对比